The US Food and Drug Administration (FDA) has approved Lantrida (donislecel), the first cell therapy for diabetes type 1. Celltrans’ treatment is now approved for use in adults with “brittle” diabetes type I, a rare form of the disease wherein patients have recurrent severe hypoglycemic episodes. The approval is based on two open-label clinical trials with 30 patients.
According to Phil Taylor, “Lantidra aims to replace the insulin-producing beta cells in the pancreas, reducing the need for insulin injections and providing a background level of insulin secretion that can help to prevent the swings between low and high blood glucose seen in unstable type 1 diabetes.”
To read more, click here.
(Source: Pharmaphorum, June 29, 2023)